Comparing two treatment combos for hard-to-remove bladder cancer
Part of Cancer clinical trials.
This study tests a new type of targeted therapy combined with immunotherapy against standard immunotherapy plus chemotherapy for people with a very high-risk, non-invasive bladder cancer that cannot be fully removed by surgery. The goal is to see if the new combination is more effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have bladder cancer that has not spread into the muscle layer, but is considered very high-risk and too large or widespread to be completely removed by surgery.
- Your cancer must test positive for a protein called HER2 (at level 1+, 2+, or 3+).
- You must not have had any previous systemic cancer treatment (like chemotherapy, immunotherapy, or targeted drugs) for your cancer.
- You should be generally well enough to carry out daily activities (performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of two drugs (rimegepant and toripalimab) for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink or control the cancer.
This study tests whether a combination of two drugs can treat bladder cancer without needing to remove the bladder. It is for people whose cancer has not spread beyond the bladder and who prefer to avoid surgery.
This study tests a new combination of an antibody-drug conjugate (a targeted therapy) with an immunotherapy drug, plus allergy and vitamin B12 medications, for advanced bladder cancer. It aims to see if this combo is safe and effective for people whose tumors have a certain marker called HER2.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.